nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—CYP1A2—Carmustine—lymphatic system cancer	0.119	0.223	CbGbCtD
Thalidomide—CYP3A5—Teniposide—lymphatic system cancer	0.108	0.201	CbGbCtD
Thalidomide—CYP2E1—Mitoxantrone—lymphatic system cancer	0.0971	0.181	CbGbCtD
Thalidomide—CYP2C19—Teniposide—lymphatic system cancer	0.087	0.162	CbGbCtD
Thalidomide—CYP2C9—Teniposide—lymphatic system cancer	0.0724	0.135	CbGbCtD
Thalidomide—CYP3A5—Vincristine—lymphatic system cancer	0.0519	0.0969	CbGbCtD
Thalidomide—Anaemia—Carmustine—lymphatic system cancer	0.000355	0.000765	CcSEcCtD
Thalidomide—Back pain—Vincristine—lymphatic system cancer	0.000355	0.000764	CcSEcCtD
Thalidomide—Vomiting—Teniposide—lymphatic system cancer	0.000354	0.000763	CcSEcCtD
Thalidomide—Sepsis—Methotrexate—lymphatic system cancer	0.000353	0.000761	CcSEcCtD
Thalidomide—Agitation—Carmustine—lymphatic system cancer	0.000353	0.00076	CcSEcCtD
Thalidomide—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000352	0.000757	CcSEcCtD
Thalidomide—Asthenia—Fludarabine—lymphatic system cancer	0.000351	0.000757	CcSEcCtD
Thalidomide—Rash—Teniposide—lymphatic system cancer	0.000351	0.000757	CcSEcCtD
Thalidomide—Dermatitis—Teniposide—lymphatic system cancer	0.000351	0.000756	CcSEcCtD
Thalidomide—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00035	0.000753	CcSEcCtD
Thalidomide—Headache—Teniposide—lymphatic system cancer	0.000349	0.000752	CcSEcCtD
Thalidomide—Pruritus—Fludarabine—lymphatic system cancer	0.000346	0.000746	CcSEcCtD
Thalidomide—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.000346	0.000746	CcSEcCtD
Thalidomide—Back pain—Mitoxantrone—lymphatic system cancer	0.000345	0.000744	CcSEcCtD
Thalidomide—Leukopenia—Carmustine—lymphatic system cancer	0.000344	0.000741	CcSEcCtD
Thalidomide—Anorexia—Bleomycin—lymphatic system cancer	0.000342	0.000737	CcSEcCtD
Thalidomide—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.000341	0.000735	CcSEcCtD
Thalidomide—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.00034	0.000732	CcSEcCtD
Thalidomide—Anaemia—Vincristine—lymphatic system cancer	0.000339	0.00073	CcSEcCtD
Thalidomide—Agitation—Vincristine—lymphatic system cancer	0.000337	0.000726	CcSEcCtD
Thalidomide—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000336	0.000725	CcSEcCtD
Thalidomide—Photosensitivity—Methotrexate—lymphatic system cancer	0.000336	0.000725	CcSEcCtD
Thalidomide—Hypotension—Bleomycin—lymphatic system cancer	0.000335	0.000723	CcSEcCtD
Thalidomide—Diarrhoea—Fludarabine—lymphatic system cancer	0.000335	0.000722	CcSEcCtD
Thalidomide—Convulsion—Carmustine—lymphatic system cancer	0.000333	0.000717	CcSEcCtD
Thalidomide—Hypertension—Carmustine—lymphatic system cancer	0.000332	0.000714	CcSEcCtD
Thalidomide—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000331	0.000714	CcSEcCtD
Thalidomide—Nausea—Teniposide—lymphatic system cancer	0.000331	0.000713	CcSEcCtD
Thalidomide—Anaemia—Mitoxantrone—lymphatic system cancer	0.00033	0.000711	CcSEcCtD
Thalidomide—Vertigo—Vincristine—lymphatic system cancer	0.000329	0.00071	CcSEcCtD
Thalidomide—Leukopenia—Vincristine—lymphatic system cancer	0.000328	0.000707	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000327	0.000705	CcSEcCtD
Thalidomide—Chest pain—Carmustine—lymphatic system cancer	0.000327	0.000704	CcSEcCtD
Thalidomide—Myalgia—Carmustine—lymphatic system cancer	0.000327	0.000704	CcSEcCtD
Thalidomide—Anxiety—Carmustine—lymphatic system cancer	0.000326	0.000702	CcSEcCtD
Thalidomide—Paraesthesia—Bleomycin—lymphatic system cancer	0.000322	0.000695	CcSEcCtD
Thalidomide—Malaise—Mitoxantrone—lymphatic system cancer	0.000322	0.000694	CcSEcCtD
Thalidomide—Dyspnoea—Bleomycin—lymphatic system cancer	0.00032	0.00069	CcSEcCtD
Thalidomide—Renal failure acute—Methotrexate—lymphatic system cancer	0.00032	0.000689	CcSEcCtD
Thalidomide—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00032	0.000688	CcSEcCtD
Thalidomide—Convulsion—Vincristine—lymphatic system cancer	0.000318	0.000684	CcSEcCtD
Thalidomide—Hypertension—Vincristine—lymphatic system cancer	0.000316	0.000682	CcSEcCtD
Thalidomide—Confusional state—Carmustine—lymphatic system cancer	0.000316	0.000681	CcSEcCtD
Thalidomide—Oedema—Carmustine—lymphatic system cancer	0.000313	0.000675	CcSEcCtD
Thalidomide—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.000313	0.000674	CcSEcCtD
Thalidomide—Decreased appetite—Bleomycin—lymphatic system cancer	0.000312	0.000672	CcSEcCtD
Thalidomide—Myalgia—Vincristine—lymphatic system cancer	0.000312	0.000672	CcSEcCtD
Thalidomide—Visual disturbance—Methotrexate—lymphatic system cancer	0.000312	0.000671	CcSEcCtD
Thalidomide—Cough—Mitoxantrone—lymphatic system cancer	0.000312	0.000671	CcSEcCtD
Thalidomide—Infection—Carmustine—lymphatic system cancer	0.000311	0.000671	CcSEcCtD
Thalidomide—Vomiting—Fludarabine—lymphatic system cancer	0.000311	0.000671	CcSEcCtD
Thalidomide—Convulsion—Mitoxantrone—lymphatic system cancer	0.000309	0.000666	CcSEcCtD
Thalidomide—Rash—Fludarabine—lymphatic system cancer	0.000309	0.000665	CcSEcCtD
Thalidomide—Dermatitis—Fludarabine—lymphatic system cancer	0.000308	0.000665	CcSEcCtD
Thalidomide—Hypertension—Mitoxantrone—lymphatic system cancer	0.000308	0.000664	CcSEcCtD
Thalidomide—Pain—Bleomycin—lymphatic system cancer	0.000307	0.000661	CcSEcCtD
Thalidomide—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000307	0.000661	CcSEcCtD
Thalidomide—Headache—Fludarabine—lymphatic system cancer	0.000307	0.000661	CcSEcCtD
Thalidomide—Tachycardia—Carmustine—lymphatic system cancer	0.000306	0.000659	CcSEcCtD
Thalidomide—Chest pain—Mitoxantrone—lymphatic system cancer	0.000304	0.000655	CcSEcCtD
Thalidomide—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000304	0.000655	CcSEcCtD
Thalidomide—Myalgia—Mitoxantrone—lymphatic system cancer	0.000304	0.000655	CcSEcCtD
Thalidomide—Anxiety—Mitoxantrone—lymphatic system cancer	0.000303	0.000653	CcSEcCtD
Thalidomide—Lethargy—Methotrexate—lymphatic system cancer	0.000301	0.000649	CcSEcCtD
Thalidomide—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.000301	0.000649	CcSEcCtD
Thalidomide—Discomfort—Mitoxantrone—lymphatic system cancer	0.0003	0.000647	CcSEcCtD
Thalidomide—Oedema—Vincristine—lymphatic system cancer	0.000299	0.000645	CcSEcCtD
Thalidomide—Anorexia—Carmustine—lymphatic system cancer	0.000299	0.000644	CcSEcCtD
Thalidomide—Infection—Vincristine—lymphatic system cancer	0.000297	0.00064	CcSEcCtD
Thalidomide—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000296	0.000637	CcSEcCtD
Thalidomide—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000295	0.000636	CcSEcCtD
Thalidomide—Confusional state—Mitoxantrone—lymphatic system cancer	0.000294	0.000633	CcSEcCtD
Thalidomide—Nervous system disorder—Vincristine—lymphatic system cancer	0.000293	0.000632	CcSEcCtD
Thalidomide—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000293	0.000631	CcSEcCtD
Thalidomide—Hypotension—Carmustine—lymphatic system cancer	0.000293	0.000631	CcSEcCtD
Thalidomide—Oedema—Mitoxantrone—lymphatic system cancer	0.000291	0.000628	CcSEcCtD
Thalidomide—Nausea—Fludarabine—lymphatic system cancer	0.000291	0.000627	CcSEcCtD
Thalidomide—Infection—Mitoxantrone—lymphatic system cancer	0.000289	0.000624	CcSEcCtD
Thalidomide—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000289	0.000623	CcSEcCtD
Thalidomide—Shock—Mitoxantrone—lymphatic system cancer	0.000287	0.000618	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000286	0.000615	CcSEcCtD
Thalidomide—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000285	0.000615	CcSEcCtD
Thalidomide—Urticaria—Bleomycin—lymphatic system cancer	0.000285	0.000615	CcSEcCtD
Thalidomide—Anorexia—Vincristine—lymphatic system cancer	0.000285	0.000614	CcSEcCtD
Thalidomide—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000284	0.000613	CcSEcCtD
Thalidomide—Body temperature increased—Bleomycin—lymphatic system cancer	0.000284	0.000611	CcSEcCtD
Thalidomide—Insomnia—Carmustine—lymphatic system cancer	0.000283	0.000611	CcSEcCtD
Thalidomide—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000283	0.00061	CcSEcCtD
Thalidomide—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000282	0.000607	CcSEcCtD
Thalidomide—Paraesthesia—Carmustine—lymphatic system cancer	0.000281	0.000606	CcSEcCtD
Thalidomide—Mood swings—Methotrexate—lymphatic system cancer	0.00028	0.000603	CcSEcCtD
Thalidomide—Hypotension—Vincristine—lymphatic system cancer	0.00028	0.000602	CcSEcCtD
Thalidomide—Dyspnoea—Carmustine—lymphatic system cancer	0.000279	0.000602	CcSEcCtD
Thalidomide—Somnolence—Carmustine—lymphatic system cancer	0.000279	0.0006	CcSEcCtD
Thalidomide—Anorexia—Mitoxantrone—lymphatic system cancer	0.000278	0.000598	CcSEcCtD
Thalidomide—Ataxia—Methotrexate—lymphatic system cancer	0.000278	0.000598	CcSEcCtD
Thalidomide—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000273	0.000587	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000273	0.000587	CcSEcCtD
Thalidomide—Decreased appetite—Carmustine—lymphatic system cancer	0.000272	0.000587	CcSEcCtD
Thalidomide—Hypotension—Mitoxantrone—lymphatic system cancer	0.000272	0.000587	CcSEcCtD
Thalidomide—Insomnia—Vincristine—lymphatic system cancer	0.000271	0.000583	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000271	0.000583	CcSEcCtD
Thalidomide—Paraesthesia—Vincristine—lymphatic system cancer	0.000269	0.000579	CcSEcCtD
Thalidomide—Pain—Carmustine—lymphatic system cancer	0.000268	0.000577	CcSEcCtD
Thalidomide—Constipation—Carmustine—lymphatic system cancer	0.000268	0.000577	CcSEcCtD
Thalidomide—Breast disorder—Methotrexate—lymphatic system cancer	0.000267	0.000575	CcSEcCtD
Thalidomide—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000266	0.000573	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000265	0.000572	CcSEcCtD
Thalidomide—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000265	0.00057	CcSEcCtD
Thalidomide—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000262	0.000564	CcSEcCtD
Thalidomide—Decreased appetite—Vincristine—lymphatic system cancer	0.00026	0.00056	CcSEcCtD
Thalidomide—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00026	0.00056	CcSEcCtD
Thalidomide—Somnolence—Mitoxantrone—lymphatic system cancer	0.000259	0.000558	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000258	0.000556	CcSEcCtD
Thalidomide—Feeling abnormal—Carmustine—lymphatic system cancer	0.000258	0.000556	CcSEcCtD
Thalidomide—Fatigue—Vincristine—lymphatic system cancer	0.000258	0.000556	CcSEcCtD
Thalidomide—Asthenia—Bleomycin—lymphatic system cancer	0.000258	0.000555	CcSEcCtD
Thalidomide—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000256	0.000553	CcSEcCtD
Thalidomide—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000256	0.000552	CcSEcCtD
Thalidomide—Constipation—Vincristine—lymphatic system cancer	0.000256	0.000551	CcSEcCtD
Thalidomide—Pain—Vincristine—lymphatic system cancer	0.000256	0.000551	CcSEcCtD
Thalidomide—Pruritus—Bleomycin—lymphatic system cancer	0.000254	0.000547	CcSEcCtD
Thalidomide—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000253	0.000546	CcSEcCtD
Thalidomide—Eosinophilia—Methotrexate—lymphatic system cancer	0.000253	0.000545	CcSEcCtD
Thalidomide—Fatigue—Mitoxantrone—lymphatic system cancer	0.000251	0.000541	CcSEcCtD
Thalidomide—Pancreatitis—Methotrexate—lymphatic system cancer	0.00025	0.000539	CcSEcCtD
Thalidomide—Constipation—Mitoxantrone—lymphatic system cancer	0.000249	0.000537	CcSEcCtD
Thalidomide—Pain—Mitoxantrone—lymphatic system cancer	0.000249	0.000537	CcSEcCtD
Thalidomide—Abdominal pain—Carmustine—lymphatic system cancer	0.000248	0.000534	CcSEcCtD
Thalidomide—Body temperature increased—Carmustine—lymphatic system cancer	0.000248	0.000534	CcSEcCtD
Thalidomide—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000245	0.000527	CcSEcCtD
Thalidomide—Pancytopenia—Methotrexate—lymphatic system cancer	0.000242	0.000522	CcSEcCtD
Thalidomide—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00024	0.000517	CcSEcCtD
Thalidomide—Neutropenia—Methotrexate—lymphatic system cancer	0.000239	0.000514	CcSEcCtD
Thalidomide—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000238	0.000513	CcSEcCtD
Thalidomide—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000237	0.000511	CcSEcCtD
Thalidomide—Abdominal pain—Vincristine—lymphatic system cancer	0.000236	0.00051	CcSEcCtD
Thalidomide—Body temperature increased—Vincristine—lymphatic system cancer	0.000236	0.00051	CcSEcCtD
Thalidomide—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000235	0.000507	CcSEcCtD
Thalidomide—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000233	0.000502	CcSEcCtD
Thalidomide—Urticaria—Mitoxantrone—lymphatic system cancer	0.000231	0.000499	CcSEcCtD
Thalidomide—Hypersensitivity—Carmustine—lymphatic system cancer	0.000231	0.000497	CcSEcCtD
Thalidomide—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00023	0.000496	CcSEcCtD
Thalidomide—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00023	0.000496	CcSEcCtD
Thalidomide—Pneumonia—Methotrexate—lymphatic system cancer	0.000229	0.000493	CcSEcCtD
Thalidomide—Vomiting—Bleomycin—lymphatic system cancer	0.000228	0.000492	CcSEcCtD
Thalidomide—Infestation NOS—Methotrexate—lymphatic system cancer	0.000228	0.00049	CcSEcCtD
Thalidomide—Infestation—Methotrexate—lymphatic system cancer	0.000228	0.00049	CcSEcCtD
Thalidomide—Drowsiness—Methotrexate—lymphatic system cancer	0.000228	0.00049	CcSEcCtD
Thalidomide—Depression—Methotrexate—lymphatic system cancer	0.000227	0.000489	CcSEcCtD
Thalidomide—Rash—Bleomycin—lymphatic system cancer	0.000226	0.000488	CcSEcCtD
Thalidomide—Dermatitis—Bleomycin—lymphatic system cancer	0.000226	0.000487	CcSEcCtD
Thalidomide—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000226	0.000486	CcSEcCtD
Thalidomide—Asthenia—Carmustine—lymphatic system cancer	0.000225	0.000484	CcSEcCtD
Thalidomide—Renal failure—Methotrexate—lymphatic system cancer	0.000224	0.000482	CcSEcCtD
Thalidomide—Stomatitis—Methotrexate—lymphatic system cancer	0.000222	0.000478	CcSEcCtD
Thalidomide—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000221	0.000477	CcSEcCtD
Thalidomide—Hypersensitivity—Vincristine—lymphatic system cancer	0.00022	0.000475	CcSEcCtD
Thalidomide—Sweating—Methotrexate—lymphatic system cancer	0.000218	0.00047	CcSEcCtD
Thalidomide—Haematuria—Methotrexate—lymphatic system cancer	0.000217	0.000468	CcSEcCtD
Thalidomide—Epistaxis—Methotrexate—lymphatic system cancer	0.000215	0.000463	CcSEcCtD
Thalidomide—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000215	0.000462	CcSEcCtD
Thalidomide—Asthenia—Vincristine—lymphatic system cancer	0.000215	0.000462	CcSEcCtD
Thalidomide—Diarrhoea—Carmustine—lymphatic system cancer	0.000214	0.000462	CcSEcCtD
Thalidomide—Nausea—Bleomycin—lymphatic system cancer	0.000213	0.000459	CcSEcCtD
Thalidomide—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000212	0.000458	CcSEcCtD
Thalidomide—Asthenia—Mitoxantrone—lymphatic system cancer	0.000209	0.00045	CcSEcCtD
Thalidomide—Dizziness—Carmustine—lymphatic system cancer	0.000207	0.000446	CcSEcCtD
Thalidomide—Diarrhoea—Vincristine—lymphatic system cancer	0.000205	0.000441	CcSEcCtD
Thalidomide—Hepatitis—Methotrexate—lymphatic system cancer	0.000204	0.00044	CcSEcCtD
Thalidomide—Pharyngitis—Methotrexate—lymphatic system cancer	0.000203	0.000437	CcSEcCtD
Thalidomide—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000202	0.000435	CcSEcCtD
Thalidomide—Urethral disorder—Methotrexate—lymphatic system cancer	0.0002	0.000432	CcSEcCtD
Thalidomide—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000199	0.000429	CcSEcCtD
Thalidomide—Vomiting—Carmustine—lymphatic system cancer	0.000199	0.000429	CcSEcCtD
Thalidomide—Dizziness—Vincristine—lymphatic system cancer	0.000198	0.000426	CcSEcCtD
Thalidomide—Rash—Carmustine—lymphatic system cancer	0.000198	0.000426	CcSEcCtD
Thalidomide—Dermatitis—Carmustine—lymphatic system cancer	0.000197	0.000425	CcSEcCtD
Thalidomide—Visual impairment—Methotrexate—lymphatic system cancer	0.000197	0.000424	CcSEcCtD
Thalidomide—Headache—Carmustine—lymphatic system cancer	0.000196	0.000423	CcSEcCtD
Thalidomide—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000193	0.000416	CcSEcCtD
Thalidomide—Eye disorder—Methotrexate—lymphatic system cancer	0.000191	0.000411	CcSEcCtD
Thalidomide—Tinnitus—Methotrexate—lymphatic system cancer	0.00019	0.00041	CcSEcCtD
Thalidomide—Vomiting—Vincristine—lymphatic system cancer	0.00019	0.00041	CcSEcCtD
Thalidomide—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00019	0.000409	CcSEcCtD
Thalidomide—Rash—Vincristine—lymphatic system cancer	0.000189	0.000406	CcSEcCtD
Thalidomide—Dermatitis—Vincristine—lymphatic system cancer	0.000188	0.000406	CcSEcCtD
Thalidomide—Headache—Vincristine—lymphatic system cancer	0.000187	0.000404	CcSEcCtD
Thalidomide—Nausea—Carmustine—lymphatic system cancer	0.000186	0.000401	CcSEcCtD
Thalidomide—Angiopathy—Methotrexate—lymphatic system cancer	0.000185	0.000399	CcSEcCtD
Thalidomide—Vomiting—Mitoxantrone—lymphatic system cancer	0.000185	0.000399	CcSEcCtD
Thalidomide—Immune system disorder—Methotrexate—lymphatic system cancer	0.000185	0.000398	CcSEcCtD
Thalidomide—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000184	0.000397	CcSEcCtD
Thalidomide—Rash—Mitoxantrone—lymphatic system cancer	0.000184	0.000396	CcSEcCtD
Thalidomide—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000184	0.000395	CcSEcCtD
Thalidomide—Chills—Methotrexate—lymphatic system cancer	0.000183	0.000395	CcSEcCtD
Thalidomide—Headache—Mitoxantrone—lymphatic system cancer	0.000183	0.000393	CcSEcCtD
Thalidomide—Alopecia—Methotrexate—lymphatic system cancer	0.000181	0.000389	CcSEcCtD
Thalidomide—Mental disorder—Methotrexate—lymphatic system cancer	0.000179	0.000386	CcSEcCtD
Thalidomide—Malnutrition—Methotrexate—lymphatic system cancer	0.000178	0.000383	CcSEcCtD
Thalidomide—Nausea—Vincristine—lymphatic system cancer	0.000178	0.000383	CcSEcCtD
Thalidomide—Dysgeusia—Methotrexate—lymphatic system cancer	0.000174	0.000375	CcSEcCtD
Thalidomide—Nausea—Mitoxantrone—lymphatic system cancer	0.000173	0.000373	CcSEcCtD
Thalidomide—Back pain—Methotrexate—lymphatic system cancer	0.000172	0.000371	CcSEcCtD
Thalidomide—Vision blurred—Methotrexate—lymphatic system cancer	0.000168	0.000361	CcSEcCtD
Thalidomide—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000165	0.000356	CcSEcCtD
Thalidomide—Anaemia—Methotrexate—lymphatic system cancer	0.000164	0.000354	CcSEcCtD
Thalidomide—Malaise—Methotrexate—lymphatic system cancer	0.00016	0.000346	CcSEcCtD
Thalidomide—Vertigo—Methotrexate—lymphatic system cancer	0.00016	0.000344	CcSEcCtD
Thalidomide—Leukopenia—Methotrexate—lymphatic system cancer	0.000159	0.000343	CcSEcCtD
Thalidomide—Cough—Methotrexate—lymphatic system cancer	0.000155	0.000334	CcSEcCtD
Thalidomide—Convulsion—Methotrexate—lymphatic system cancer	0.000154	0.000332	CcSEcCtD
Thalidomide—Chest pain—Methotrexate—lymphatic system cancer	0.000151	0.000326	CcSEcCtD
Thalidomide—Arthralgia—Methotrexate—lymphatic system cancer	0.000151	0.000326	CcSEcCtD
Thalidomide—Myalgia—Methotrexate—lymphatic system cancer	0.000151	0.000326	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.00015	0.000324	CcSEcCtD
Thalidomide—Discomfort—Methotrexate—lymphatic system cancer	0.00015	0.000322	CcSEcCtD
Thalidomide—Confusional state—Methotrexate—lymphatic system cancer	0.000146	0.000315	CcSEcCtD
Thalidomide—Infection—Methotrexate—lymphatic system cancer	0.000144	0.000311	CcSEcCtD
Thalidomide—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000142	0.000307	CcSEcCtD
Thalidomide—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000142	0.000306	CcSEcCtD
Thalidomide—Skin disorder—Methotrexate—lymphatic system cancer	0.000141	0.000304	CcSEcCtD
Thalidomide—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00014	0.000302	CcSEcCtD
Thalidomide—Anorexia—Methotrexate—lymphatic system cancer	0.000138	0.000298	CcSEcCtD
Thalidomide—Hypotension—Methotrexate—lymphatic system cancer	0.000136	0.000292	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000132	0.000285	CcSEcCtD
Thalidomide—Insomnia—Methotrexate—lymphatic system cancer	0.000131	0.000283	CcSEcCtD
Thalidomide—Paraesthesia—Methotrexate—lymphatic system cancer	0.00013	0.000281	CcSEcCtD
Thalidomide—Dyspnoea—Methotrexate—lymphatic system cancer	0.000129	0.000279	CcSEcCtD
Thalidomide—Somnolence—Methotrexate—lymphatic system cancer	0.000129	0.000278	CcSEcCtD
Thalidomide—Dyspepsia—Methotrexate—lymphatic system cancer	0.000128	0.000275	CcSEcCtD
Thalidomide—Decreased appetite—Methotrexate—lymphatic system cancer	0.000126	0.000272	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000125	0.00027	CcSEcCtD
Thalidomide—Fatigue—Methotrexate—lymphatic system cancer	0.000125	0.00027	CcSEcCtD
Thalidomide—Pain—Methotrexate—lymphatic system cancer	0.000124	0.000267	CcSEcCtD
Thalidomide—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00012	0.000258	CcSEcCtD
Thalidomide—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000119	0.000256	CcSEcCtD
Thalidomide—Urticaria—Methotrexate—lymphatic system cancer	0.000115	0.000248	CcSEcCtD
Thalidomide—Abdominal pain—Methotrexate—lymphatic system cancer	0.000115	0.000247	CcSEcCtD
Thalidomide—Body temperature increased—Methotrexate—lymphatic system cancer	0.000115	0.000247	CcSEcCtD
Thalidomide—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000107	0.00023	CcSEcCtD
Thalidomide—Asthenia—Methotrexate—lymphatic system cancer	0.000104	0.000224	CcSEcCtD
Thalidomide—Pruritus—Methotrexate—lymphatic system cancer	0.000103	0.000221	CcSEcCtD
Thalidomide—Diarrhoea—Methotrexate—lymphatic system cancer	9.93e-05	0.000214	CcSEcCtD
Thalidomide—Dizziness—Methotrexate—lymphatic system cancer	9.6e-05	0.000207	CcSEcCtD
Thalidomide—Vomiting—Methotrexate—lymphatic system cancer	9.23e-05	0.000199	CcSEcCtD
Thalidomide—Rash—Methotrexate—lymphatic system cancer	9.15e-05	0.000197	CcSEcCtD
Thalidomide—Dermatitis—Methotrexate—lymphatic system cancer	9.14e-05	0.000197	CcSEcCtD
Thalidomide—Headache—Methotrexate—lymphatic system cancer	9.09e-05	0.000196	CcSEcCtD
Thalidomide—Nausea—Methotrexate—lymphatic system cancer	8.62e-05	0.000186	CcSEcCtD
